These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18375654)

  • 1. Maintaining confidentiality of interim data to enhance trial integrity and credibility.
    Fleming TR; Sharples K; McCall J; Moore A; Rodgers A; Stewart R
    Clin Trials; 2008; 5(2):157-67. PubMed ID: 18375654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting the confidentiality of interim data: addressing current challenges.
    Fleming TR
    Clin Trials; 2015 Feb; 12(1):5-11. PubMed ID: 25475877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data Monitoring Committees: Current issues.
    Fleming TR; Ellenberg SS; DeMets DL
    Clin Trials; 2018 Aug; 15(4):321-328. PubMed ID: 29629815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in data monitoring and interim analysis of trials.
    Grant AM; Altman DG; Babiker AB; Campbell MK; Clemens FJ; Darbyshire JH; Elbourne DR; McLeer SK; Parmar MK; Pocock SJ; Spiegelhalter DJ; Sydes MR; Walker AE; Wallace SA;
    Health Technol Assess; 2005 Mar; 9(7):1-238, iii-iv. PubMed ID: 15763038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring clinical trials: issues and controversies regarding confidentiality.
    Fleming TR; Ellenberg S; DeMets DL
    Stat Med; 2002 Oct; 21(19):2843-51. PubMed ID: 12325100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on 'maintaining confidentiality of interim data to enhance trial integrity and credibility' by TR Fleming et al.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    Clin Trials; 2008; 5(4):364-5; author reply 365-6. PubMed ID: 18697851
    [No Abstract]   [Full Text] [Related]  

  • 8. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sharing interim trial results by the Data Safety Monitoring Board with those responsible for the trial's conduct and progress: a narrative review.
    Borg Debono V; Mbuagbaw L; Thabane L
    Trials; 2017 Mar; 18(1):120. PubMed ID: 28279205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential?
    Stephens RJ; Langley RE; Mulvenna P; Nankivell M; Vail A; Parmar MK
    Lung Cancer; 2014 Aug; 85(2):116-8. PubMed ID: 24908333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major trial needs three statisticians: why, how and who?
    Pocock SJ
    Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias.
    Tharmanathan P; Calvert M; Hampton J; Freemantle N
    BMC Med Res Methodol; 2008 Mar; 8():12. PubMed ID: 18366697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "You have to keep your nerve on a DMC." Challenges for Data Monitoring Committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study.
    Snowdon C; Brocklehurst P; Tasker RC; Ward Platt M; Elbourne D
    PLoS One; 2018; 13(7):e0201037. PubMed ID: 30048484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: confidentiality of interim trial data-the emerging crisis.
    Nissen SE
    Clin Trials; 2015 Feb; 12(1):15-7. PubMed ID: 25525072
    [No Abstract]   [Full Text] [Related]  

  • 17. Standard versus adaptive monitoring procedures: A commentary.
    Fleming TR
    Stat Med; 2006 Oct; 25(19):3305-12; discussion 3313-4, 3326-47. PubMed ID: 16850447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should data and safety monitoring boards share confidential interim data?
    Dixon DO; Lagakos SW
    Control Clin Trials; 2000 Feb; 21(1):1-6; discussion 54-5. PubMed ID: 10659999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Data monitoring committees for pragmatic clinical trials.
    Ellenberg SS; Culbertson R; Gillen DL; Goodman S; Schrandt S; Zirkle M
    Clin Trials; 2015 Oct; 12(5):530-6. PubMed ID: 26374679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Independent data monitoring committees: an update and overview.
    Sartor O; Halabi S
    Urol Oncol; 2015 Mar; 33(3):143-8. PubMed ID: 25631301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.